智通财经网·2025-11-13 08:56Core Viewpoint - The company, CanSino Biologics, has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine (5-type adenovirus vector) has officially started Phase I clinical trials in Indonesia, with the first subject enrolled [1] - Currently, the only vaccine available for tuberculosis prevention globally is the BCG vaccine, which has limitations in long-term efficacy and cannot be enhanced through booster shots [1] - The company has developed a first-generation innovative tuberculosis booster vaccine aimed at BCG-vaccinated populations, which has completed Phase Ia and Ib clinical trials in Canada, demonstrating safety and efficacy as a booster [1] Group 2: Technology and Delivery Method - The company has leveraged technology from its inhaled COVID-19 vaccine development to establish a comprehensive inhalation pharmaceutical and quality control system, enhancing the first-generation product and adding antigen components [1] - The inhaled tuberculosis booster vaccine is designed to be delivered via nebulization, which is expected to stimulate pulmonary immune responses to eliminate tuberculosis bacteria and control latent infections [1] Group 3: Clinical Trial Objectives - The Phase I clinical trial aims to investigate the safety and immunogenicity of a single dose of the inhaled tuberculosis booster vaccine in adults aged 18 to 49 [1]